Trial Profile

An Exploratory Clinical Study on the Safety and Efficacy of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Autoimmune Neurological Diseases

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 10 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Inaticabtagene autoleucel (Primary)
Indications Autoimmune diseases of the nervous system; Chronic inflammatory demyelinating polyradiculoneuropathy; Multiple sclerosis; Myasthenia gravis; Neuromyelitis optica
Focus Adverse reactions
Sponsors Juventas Cell Therapy

Most Recent Events

05 Mar 2026 Status changed from not yet recruiting to recruiting.
18 Dec 2025 Planned initiation date changed from 29 Nov 2025 to 15 Dec 2025.
16 Dec 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com